Shem Patyna

3.7k total citations · 1 hit paper
32 papers, 2.6k citations indexed

About

Shem Patyna is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shem Patyna has authored 32 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Epidemiology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shem Patyna's work include Lung Cancer Research Studies (14 papers), Neuroendocrine Tumor Research Advances (13 papers) and Neuroblastoma Research and Treatments (8 papers). Shem Patyna is often cited by papers focused on Lung Cancer Research Studies (14 papers), Neuroendocrine Tumor Research Advances (13 papers) and Neuroblastoma Research and Treatments (8 papers). Shem Patyna collaborates with scholars based in United States, United Kingdom and France. Shem Patyna's co-authors include Richard C. Chao, Juan W. Valle, Jean‐Luc Raoul, Ivan Borbath, Éric Raymond, Catherine Lombard‐Bohas, Eric Van Cutsem, Yung‐Jue Bang, Peter Metrakos and Denis Smith and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Shem Patyna

32 papers receiving 2.6k citations

Hit Papers

Sunitinib Malate for the Treatment of Pancreatic Neuroend... 2011 2026 2016 2021 2011 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
    2011 1.8k citations Éric Raymond, Laëtitia Dahan et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shem Patyna United States 15 1.9k 1.6k 1.1k 541 393 32 2.6k
James Posey United States 26 1.8k 0.9× 957 0.6× 620 0.5× 723 1.3× 412 1.0× 66 2.7k
Sakina Hoosen United States 6 2.2k 1.1× 2.2k 1.4× 1.5k 1.3× 565 1.0× 276 0.7× 7 2.9k
Richard C. Chao United States 28 2.9k 1.5× 1.7k 1.1× 1.2k 1.1× 1.3k 2.3× 1.4k 3.5× 90 4.1k
Roberto Franchi Italy 25 987 0.5× 545 0.3× 471 0.4× 222 0.4× 637 1.6× 68 2.4k
Pamela L. Kunz United States 33 2.9k 1.5× 2.5k 1.6× 1.8k 1.5× 294 0.5× 712 1.8× 101 4.1k
Isabel Sevilla Spain 19 951 0.5× 551 0.4× 437 0.4× 194 0.4× 328 0.8× 83 1.4k
L. Tye United States 18 1.2k 0.6× 489 0.3× 353 0.3× 550 1.0× 1.0k 2.6× 43 1.9k
Naris Nilubol United States 35 1.3k 0.7× 1.3k 0.8× 758 0.7× 909 1.7× 297 0.8× 162 4.0k
C. Lombard Bohas France 6 1.7k 0.9× 1.7k 1.1× 1.2k 1.0× 434 0.8× 205 0.5× 17 2.2k
Ralf J. Rieker Germany 27 694 0.4× 369 0.2× 485 0.4× 738 1.4× 435 1.1× 91 2.2k

Countries citing papers authored by Shem Patyna

Since Specialization
Citations

This map shows the geographic impact of Shem Patyna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shem Patyna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shem Patyna more than expected).

Fields of papers citing papers by Shem Patyna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shem Patyna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shem Patyna. The network helps show where Shem Patyna may publish in the future.

Co-authorship network of co-authors of Shem Patyna

This figure shows the co-authorship network connecting the top 25 collaborators of Shem Patyna. A scholar is included among the top collaborators of Shem Patyna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shem Patyna. Shem Patyna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fein, Luis, Nicolas Lazaretti, John R. Benfield, et al.. (2023). Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate. Clinical Drug Investigation. 43(9). 699–706. 3 indexed citations
2.
Raymond, Éric, Patricia Niccoli, Daniel Castellano, et al.. (2016). Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.. Journal of Clinical Oncology. 34(4_suppl). 309–309. 8 indexed citations
3.
Michaelson, M. Dror, Andrew X. Zhu, David P. Ryan, et al.. (2013). Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. British Journal of Cancer. 108(7). 1393–1401. 18 indexed citations
4.
Vinik, Aaron I., Eric Van Cutsem, Patricia Niccoli, et al.. (2012). Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET). Pancreas. 41(2). 350–350. 4 indexed citations
5.
Faivre, Sandrine, Patricia Niccoli, Jean‐Luc Raoul, et al.. (2012). Updated Overall Survival (OS) Analysis from a Phase III Study of Sunitinib vs Placebo in Patients (PTS) with Advanced, Unresectable Pancreatic Neuroendocrine Tumor (NET). Annals of Oncology. 23. ix376–ix376. 4 indexed citations
6.
Hammel, Pascal, Daniel Castellano, Eric Van Cutsem, et al.. (2011). Evaluation of Progression-Free Survival by Blinded Independent Central Review in Patients With Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors Treated With Sunitinib or Placebo. Pancreas. 40(2). 327–327. 2 indexed citations
7.
Valle, Juan W., Patricia Niccoli, Jean‐Luc Raoul, et al.. (2011). Updated Overall Survival Data From a Phase III Study of Sunitinib Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET). European Journal of Cancer. 47. 2 indexed citations
8.
Blasi, Francesco, Jonathan R. Heyen, Shem Patyna, et al.. (2011). Sunitinib, a Receptor Tyrosine Kinase Inhibitor, Increases Blood Pressure in Rats without Associated Changes in Cardiac Structure and Function. Cardiovascular Therapeutics. 30(5). 287–294. 23 indexed citations
9.
Novello, Silvia, Carlos Camps, Francesco Grossi, et al.. (2011). Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases. Journal of Thoracic Oncology. 6(7). 1260–1266. 41 indexed citations
10.
Bu, Hai‐Zhi, William F. Pool, Geoffrey W. Peng, et al.. (2011). Pharmacokinetics, Distribution, and Metabolism of [14C]Sunitinib in Rats, Monkeys, and Humans. Drug Metabolism and Disposition. 40(3). 539–555. 85 indexed citations
11.
Raymond, Éric, Laëtitia Dahan, Jean‐Luc Raoul, et al.. (2011). Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. New England Journal of Medicine. 364(6). 501–513. 1798 indexed citations breakdown →
12.
13.
Patyna, Shem, et al.. (2009). Evaluation of the safety and pharmacokinetics of the multi‐targeted receptor tyrosine kinase inhibitor sunitinib during embryo–fetal development in rats and rabbits. Birth Defects Research Part B Developmental and Reproductive Toxicology. 86(3). 204–213. 37 indexed citations
14.
Haznedar, Joshua, Shem Patyna, Carlo L. Bello, et al.. (2009). Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemotherapy and Pharmacology. 64(4). 691–706. 56 indexed citations
15.
Novello, Silvia, Lauren E. Abrey, Francesco Grossi, et al.. (2009). Administration of sunitinib to patients with non-small cell lung cancer and irradiated brain metastases: A phase II trial. Journal of Clinical Oncology. 27(15_suppl). 8077–8077. 4 indexed citations
16.
Speed, William C., Carlo L. Bello, Geoffrey W. Peng, Shem Patyna, & Ellen Y. Wu. (2008). In vitro and in vivo metabolism of sunitinib in nonclinical species and humans. Cancer Research. 68. 1285–1285. 3 indexed citations
17.
Will, Yvonne, James A. Dykens, Sashi Nadanaciva, et al.. (2008). Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells. Toxicological Sciences. 106(1). 153–161. 171 indexed citations
18.
Bello, Carlo L., Hai‐Zhi Bu, Shem Patyna, et al.. (2007). A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib (SU11248) in healthy male subjects. Cancer Research. 67. 6 indexed citations
19.
Patyna, Shem & Geoffrey W. Peng. (2006). 56 POSTER Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intrvenous administration in rodents and monkeys. European Journal of Cancer Supplements. 4(12). 21–21. 31 indexed citations
20.
Duan, W. Rachel, et al.. (2006). A Multitargeted Receptor Tyrosine Kinase Inhibitor, SU6668, Does Not Affect the Healing of Cutaneous Full-Thickness Incisional Wounds in SKH-1 Mice. Journal of Investigative Surgery. 19(4). 245–254. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James Posey Breakdown of academic impact, for papers by Sakina Hoosen Breakdown of academic impact, for papers by Richard C. Chao Breakdown of academic impact, for papers by Roberto Franchi Breakdown of academic impact, for papers by Pamela L. Kunz Breakdown of academic impact, for papers by Isabel Sevilla Breakdown of academic impact, for papers by L. Tye Breakdown of academic impact, for papers by Naris Nilubol Breakdown of academic impact, for papers by C. Lombard Bohas Breakdown of academic impact, for papers by Ralf J. Rieker
Rankless by CCL
2026